KNBWF News and Press, Kirin Holdings Co Ltd

2023-09-24 23:33:31 ET Summary Kyowa Kirin shares are viewed as a cheap option on the positive outcome for the atopic dermatitis drug being developed with Amgen. The company's recent track record for new drug trial success has been poor, but the partnership with Amgen provides rea...

2023-04-25 04:31:23 ET Summary Kirin Holdings is executing positive price hikes, business portfolio management, and a greater commitment to raising profitability. Earnings visibility looks positive, with continued price increases in beverages, steady overseas expansion, and steady...

Summary The Seeking Alpha Quant system has its quirks, but it is a great tool to find holdings. I will discuss the performance of the five holdings I covered in the prior article. Also, at the end, I will provide some interesting literature discussing the Seeking Alpha platform as a...

The following slide deck was published by Kirin Holdings Company, Limited in conjunction with their 2022 Q3 earnings call. For further details see: Kirin Holdings Company, Limited 2022 Q3 - Results - Earnings Call Presentation

The Seeking Alpha Quant system has its quirks, but it is a great tool to find great holdings. I typically dredge through the weeds to find unique situations that may be unloved by the quant system. However, here are five strong buys that I agree with right now. Optimizin...

Kirin announced a credible medium-term plan, highlighting opportunities for growth and improving profitability. There are limits to what Kirin can achieve in the face of current inflationary cost pressures, and the domestic price hike announcement highlights its significance. Cons...

The following slide deck was published by Kirin Holdings Company, Limited in conjunction with their 2022 Q1 earnings call. For further details see: Kirin Holdings Company, Limited 2022 Q1 - Results - Earnings Call Presentation

Kirin Holdings Company press release (OTCPK:KNBWY): Q1 GAAP EPS of ¥29.84. Revenue of ¥87.75B (+8.2% Y/Y). For further details see: Kirin Holdings Company GAAP EPS of ¥29.84, revenue of ¥87.75B

Molson Coors represents a bargain play in the nearly recession-proof alcoholic beverage industry. A nearly 3% dividend and 9% free cash flow yield are available to intelligent investors (roughly double the prevailing S&P 500 rates). Technical trading momentum has improved dram...

Early indications show that Kyowa Kirin has a blockbuster drug with KHK4083, a treatment for severe atopic dermatitis (eczema). Phase 2 trials have shown encouraging results and the agreement to jointly develop and commercialize the drug with Amgen is a positive signal. With both ...